Chagas Disease in Spain: Need for Further Public Health Measures

Navarro, Miriam; Navaza, Bárbara; Guionnet, Anne; López‐Vélez, Rogelio

doi:10.1371/journal.pntd.0001962

Cited by 65 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Sicuri et al (59), 1.7 million migrants from Latin American countries endemic for Chagas disease live in Spain, where 42,173 adult immigrants are estimated to be infected with T. cruzi (64). By 2009, an estimated 68,000 to 122,000 Latin American immigrants in Europe were thought to be infected by T. cruzi, but only 4,290 of them were diagnosed (65).…”

Section: Discussionmentioning

confidence: 99%

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

et al. 2016

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

et al. 2016

View full text Add to dashboard Cite

“…Intense human migration from areas where the disease is endemic to countries where it is not endemic contributes to CD expansion. Recently, several cases have been diagnosed in North America, Oceania, and some countries of Asia and Europe (3) due to vector-independent transmission mechanisms, such as congenital, blood transfusion, organ transplant, and other transmissions (4,5).…”

mentioning

confidence: 99%

Efficacy of Lychnopholide Polymeric Nanocapsules after Oral and Intravenous Administration in Murine Experimental Chagas Disease

Mello

Branquinho

Oliveira

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The etiological treatment of Chagas disease remains neglected. The compounds available show several limitations, mainly during the chronic phase. Lychnopholide encapsulated in polymeric nanocapsules (LYC-NC) was efficacious in mice infected with Trypanosoma cruzi and treated by intravenous administration during the acute phase (AP). As the oral route is preferred for treatment of chronic infections, such as Chagas disease, this study evaluated the use of oral LYC-NC in the AP and also compared it with LYC-NC administered to mice by the oral and intravenous routes during the chronic phase (CP). The therapeutic efficacy was evaluated by fresh blood examination, hemoculture, PCR, and enzyme-linked immunosorbent assay (ELISA). The cure rates in the AP and CP were 62.5% and 55.6%, respectively, upon oral administration of LYC-poly(D,L-lactide)-polyethylene glycol nanocapsules (LYC-PLA-PEG-NC) and 57.0% and 30.0%, respectively, with LYC-poly--caprolactone nanocapsules (LYC-PCL-NC). These cure rates were significantly higher than that of free LYC, which did not cure any animals. LYC-NC formulations administered orally during the AP showed cure rates similar to that of benznidazole, but only LYC-NC cured mice in the CP. Similar results were achieved with intravenous treatment during the CP. The higher cure rates obtained with LYC loaded in PLA-PEG-NC may be due to the smaller particle size of these NC and the presence of PEG, which influence tissue diffusion and the controlled release of LYC. Furthermore, PLA-PEG-NC may improve the stability of the drug in the gastrointestinal tract. This work is the first report of cure of experimental Chagas disease via oral administration during the CP. These findings represent a new and important perspective for oral treatment of Chagas disease.

show abstract

“…Dicha seroprevalencia probablemente difiere de los reportes en los países de Latinoamérica y está estrechamente vinculada con el país y la región de origen (25).…”

Section: Discussionunclassified

Anti-Trypanosoma cruzi antibodies in Latin American migrants in transit through the México- USA border

2018

View full text Add to dashboard Cite

Introducción. En los últimos años, la tripanosomiasis americana se ha convertido en un problema de salud pública emergente en países receptores de poblaciones migrantes, como México, Estados Unidos, Canadá y los países europeos.Objetivo. Analizar la prevalencia de anticuerpos anti-Trypanosoma cruzi mediante técnicas serológicas, en los migrantes latinos en su paso hacia Estados Unidos y Canadá.Materiales y métodos. Se hicieron análisis serológicos mediante ELISA y la prueba de hemaglutinación indirecta (HAI) para detectar anticuerpos anti-T. cruzi, y encuestas socioeconómicas para determinar los factores asociados a los casos seropositivos que favorecieron la transmisión en el país de origen de los migrantes.Resultados. La seroprevalencia total en la población estudiada fue del 20 % (24/120). La prevalencia más alta se encontró en migrantes de Guatemala, con 37,5 % (6/16), seguidos de los de Honduras (22,6 %; 12/53), El Salvador (16 %; 4/25) y México (8,7 %; 3/23). De los 120 migrantes encuestados, 105 (87,5 %) reconocieron el vector y 62 (59 %) afirmaron haber sido picados por este. La asociación de la infección con los materiales de construcción de las paredes de las viviendas, así como con la presencia de mascotas (perros) en los hogares, fue muy significativa (p≤0,01). La asociación con el material de construcción del patio, los servicios básicos precarios, así como la cría de animales dentro de corrales en la periferia de los hogares, también fue significativa (p≤0,05).Conclusión. Los países no endémicos que reciben migrantes de zonas endémicas deben mejorar o desarrollar políticas de salud para prevenir la transmisión del parásito por transfusión o por vía congénita.

show abstract

Chagas Disease in Spain: Need for Further Public Health Measures

Cited by 65 publications

References 15 publications

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change?

Efficacy of Lychnopholide Polymeric Nanocapsules after Oral and Intravenous Administration in Murine Experimental Chagas Disease

Anti-Trypanosoma cruzi antibodies in Latin American migrants in transit through the México- USA border

Contact Info

Product

Resources

About